Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Validation master plan (VMP): inspection expectations in 2026

This article explains how validation governance supports inspection readiness by aligning validation strategy, GMP documentation, and lifecycle oversight. It focuses on inspection expectations, decision traceability, and how pharmaceutical manufacturers use structured validation planning to reduce audit risk.
  • Blog, Validation and Qualification
GMP validation documentation and validation lifecycle approach supporting inspection readiness and audit evidence in pharmaceutical manufacturing.

Nitrosamine compounds: formation and inspection focus in 2026

This article explains how impurity formation risks emerge during pharmaceutical manufacturing and why GMP inspectors focus on formation logic, traceable decisions, and lifecycle controls. It provides an inspection-oriented view of regulatory expectations and common quality system gaps.
  • Blog, GMP, Nitrosamine
How nitrosamine impurities are formed in pharmaceutical manufacturing and reviewed during GMP inspections

Nitrosamine in pharmaceuticals: A Strategic Compliance View in 2026

Nitrosamine oversight has become a critical focus for regulators worldwide. This article explains how inspection expectations, pharmacovigilance governance, and evidence traceability shape regulatory decisions and long-term compliance strategies across pharmaceutical product lifecycles.
  • Blog, Nitrosamine
Quality and regulatory teams overseeing quality system oversight nitrosamines during pharmaceutical compliance review.

Method Validation in Pharma in 2026: GMP Inspection View

GMP inspections increasingly highlight gaps in pharmaceutical analytical validation. This article explains how regulators evaluate validation documentation, acceptance criteria, and lifecycle management, and why weaknesses in analytical method performance often escalate into formal inspection findings.
  • Blog, GMP, Validation and Qualification
GMP inspection findings caused by pharmaceutical analytical validation weaknesses, showing issues with validation documentation, acceptance criteria, and analytical method performance in regulated laboratories.

Pharma Validation as a Strategic Compliance System in 2026

This article examines pharmaceutical validation as a governance-driven compliance system, exploring lifecycle validation management, regulatory expectations, and inspection readiness. It offers strategic insight into how validation maturity, data integrity, and oversight architecture shape regulatory confidence across pharmaceutical quality systems.
  • Blog, GMP, Validation and Qualification
Pharmaceutical compliance architecture illustrating lifecycle validation management, regulatory oversight, and inspection readiness within GMP environments

RMP in Pharmacovigilance in 2026: Regulatory Findings

This article explains how a pharmacovigilance risk management plan supports inspection readiness. It explores EU RMP pharmacovigilance expectations, RMP effectivenes evaluation, additional risk minimisation measures, and common pharmacovigilance inspection findings linked to weak RMP lifecycle management.
  • Blog, GMP, Quality Management System
Drug safety risk management plan illustrating EMA RMP requirements, effectiveness evaluation, and lifecycle management during pharmacovigilance inspections

Signal Detection in Pharmacovigilance in 2026: Inspection Findings

Pharmacovigilance inspections increasingly identify gaps in signal management processes. This article explains how safety signal detection failures lead to inspection findings and outlines regulatory expectations, surveillance system requirements, and practical approaches to improve inspection readiness.
  • Blog, GMP, Quality Management System
Pharmacovigilance inspection scenario showing safety signal detection process, regulatory review of drug safety data, and weaknesses in pharmacovigilance surveillance systems identified during inspections.

Shelf Life Determination in 2026: GMP Stability Focus

This article explains how stability studies GMP support shelf life justification during inspections. It examines pharmaceutical stability testing, ongoing stability programs, and common GMP inspection observations when expiration date assignment lacks scientific or regulatory support.
  • Blog, GMP, Quality Management System
GMP stability requirements illustrated through pharmaceutical stability testing, ongoing stability program review, and regulatory evaluation of expiry decisions